SUNPHARMA Share Price, Analysis & Fundamentals

Despite recent monthly declines and weak momentum, Sun Pharma shows accumulation signs, supported by strong year-on-year fundamentals and a predominantly bullish analyst outlook.

The stock's short-term returns show a slight gain of 0.11% over the last day, but this is overshadowed by a -3.69% decline over the past month, indicating a recent downtrend.
Technical indicators suggest weak momentum, with an RSI of 43.27 and a bearish MACD signal, implying that the price may continue to fall.
Despite a neutral trend and weak momentum, there's a notable accumulation in delivery volumes at 59.05%, suggesting underlying buying interest despite the bearish technicals.
Quarterly fundamentals present a mixed picture: while year-on-year revenue, net profit, and EPS show robust growth of 12.756%, 25.812%, and 26.228% respectively, quarter-on-quarter metrics reveal a decline.
Analysts maintain a predominantly bullish outlook, with 87.5% of ratings being Strong Buy or Buy, a distribution that has remained stable over the past month.
Recent news highlights include sector-wide discussions on healthcare innovation and market themes for 2026, though these do not provide direct company-specific catalysts.

The stock experienced a short-term return of 0.11% in the last day, but has seen a decline of -3.69% over the past month.
The trend is neutral, with the price below the 9-day and 21-day EMAs, and a negative trend alignment score.
Momentum is weak, indicated by an RSI of 43.27 and a bearish MACD signal.
Volatility is moderate, with the price positioned at 16.15% of the Bollinger Band width, and the 20-day annualized volatility at 18.44%.
The stock is trading 6.18% below its 52-week high and is currently in a drawdown of -6.18%. Average 20-day delivery volume is 59.05% with accumulation noted.

The stock exhibits a neutral trend and weak momentum, with the price trading below key EMAs and showing bearish signals from the MACD. While volatility is moderate and the stock is within its Bollinger Bands, it is also approaching its 52-week low, indicating potential downside risk. The accumulation noted in delivery volumes suggests some underlying buying interest despite the bearish technicals.

Revenue in Mar 2026 quarter was ₹14,612 Cr.
Quarter-on-quarter, revenue decreased by -5.857%, net profit by -19.846%, and EPS by -19.444%.
Year-on-year, revenue grew by 12.756%, net profit by 25.812%, and EPS by 26.228%.
Profitability shows a positive year-on-year trend with net profit up 25.812%.

The company has released the transcript for its analyst meet held on May 22, 2026, as per Regulation 30 of LODR. This announcement was made on May 29, 2026.